Interobserver Agreement of the Eczema Area and Severity Index for Atopic Dermatitis Severity Assessment: A Real-World Evidence Study
Dermatitis® · 2026
DOI: 10.1089/derm.2025.0054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatitis®, 2026. Verfasst von Jose Maria Villa-Gonzalez und 21 weiteren Autor:innen. Beteiligte Einrichtung: From the, Department of Dermatology, Cruces University Hospital, Barakaldo, Spain. Hauptthemen laut MEDLINE: Severity of Illness Index, Dermatitis, Atopic, Eczema. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background
The Eczema Area and Severity Index (EASI) has been suggested to show a good to excellent level of concordance. However, in everyday clinical practice, there is a perceived low level of concordance.
Objective
To assess the degree of concordance in the EASI scores in a real-world clinical setting.
Methods
This transversal study assesses interobserver concordance of EASI among 5 evaluators between January and October 2024.
Results
For the head and neck area, unacceptable concordance was found for all the items in EASI. In the trunk area, there was acceptable concordance for the affected surface area (0.686 [95% confidence interval {CI}: 0.539–0.799]) but unacceptable concordance for the other items. For the upper and lower extremities, unacceptable concordance was observed for all items. The total EASI interclass correlation coefficient showed moderate concordance (0.754 [95% CI: 0.659–0.838]). Despite moderate concordance for the total EASI score, the median EASI range for the same patient was 13, indicating significant heterogeneity between evaluators. Discussion and Conclusion: This study highlights the variability of the EASI in the evaluation of atopic dermatitis (AD) in a real-world clinical practice setting, suggesting that patient-reported outcome measures and experiences should be given more importance as additional AD severity measures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- From the, Department of Dermatology, Cruces University Hospital, Barakaldo, Spain.
- Bioinformatics, biostatistics and information systems platform, Biobizkaia Health Research Institute, Barakaldo, Spain.
ORCID-Profile: Jose Maria Villa-Gonzalez
Zitieren
APA
Villa-Gonzalez, J. M., Gonzalez-Hermosa, M. R., Ugedo Alzaga, J., Pérez Blasco, R., Andrés Ibarrola, P., Atxutegi Ayesta, X., García García, A., Irizar Aguirre, I., Udondo González Del Tánago, B., Pascual Ares, M., Allende Markixana, I., Acebo Mariñas, E., Díaz Ramón, J. L., Mendieta Eckert, M., Navajas Pinedo, B., Eizaguirre Uriarte, X., Ocerin Guerra, I., Agesta Sánchez, N., Álvarez Sánchez, S., …, & Ratón Nieto, J. A. (2026). Interobserver Agreement of the Eczema Area and Severity Index for Atopic Dermatitis Severity Assessment: A Real-World Evidence Study. Dermatitis®. https://doi.org/10.1089/derm.2025.0054
Vancouver
Villa-Gonzalez JM, Gonzalez-Hermosa MR, Ugedo Alzaga J, Pérez Blasco R, Andrés Ibarrola P, Atxutegi Ayesta X, et al. Interobserver Agreement of the Eczema Area and Severity Index for Atopic Dermatitis Severity Assessment: A Real-World Evidence Study. Dermatitis®. 2026. doi:10.1089/derm.2025.0054
BibTeX
@article{VillaGonzalez2026,
author = {Villa-Gonzalez, Jose Maria and Gonzalez-Hermosa, Maria Rosario and Ugedo Alzaga, Joseba and Pérez Blasco, Rebeca and Andrés Ibarrola, Patricia and Atxutegi Ayesta, Xabier and García García, Alberto and Irizar Aguirre, Irati and Udondo González Del Tánago, Begoña and Pascual Ares, Manuel and Allende Markixana, Irati and Acebo Mariñas, Elvira and Díaz Ramón, Jose Luís and Mendieta Eckert, Marta and Navajas Pinedo, Belen and Eizaguirre Uriarte, Xabier and Ocerin Guerra, Izaskun and Agesta Sánchez, Nerea and Álvarez Sánchez, Salomé and Lasa Elgezua, Olatz and Santos-Zorrozúa, Borja and Ratón Nieto, Juan Antonio},
title = {Interobserver Agreement of the Eczema Area and Severity Index for Atopic Dermatitis Severity Assessment: A Real-World Evidence Study},
journal = {Dermatitis®},
year = {2026},
doi = {10.1089/derm.2025.0054}
}
EUVIMED